Yong Y Han Selected Research

Shock

12/2018	Interhospital Transfer of Children in Septic Shock: A Clinician Interview Qualitative Study.
6/2011	A normal capillary refill time of ≤ 2 seconds is associated with superior vena cava oxygen saturations of ≥ 70%.
8/2009	Mortality and functional morbidity after use of PALS/APLS by community physicians.
2/2009	Clinical practice parameters for hemodynamic support of pediatric and neonatal septic shock: 2007 update from the American College of Critical Care Medicine.
10/2003	Early reversal of pediatric-neonatal septic shock by community physicians is associated with improved outcome.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yong Y Han Research Topics

Disease

5	Shock 12/2018 - 10/2003
4	Sepsis (Septicemia) 05/2015 - 05/2002
3	Septic Shock (Toxic Shock Syndrome) 12/2018 - 10/2003
3	Multiple Organ Failure (MODS) 05/2015 - 01/2003
2	Cerebrospinal Fluid Leak 07/2012 - 01/2002
2	Critical Illness (Critically Ill) 04/2012 - 10/2008
2	Thrombotic Microangiopathies 01/2011 - 10/2008
1	Clinical Deterioration 01/2017
1	Respiratory Insufficiency (Respiratory Failure) 01/2017
1	Hyperventilation 07/2012
1	Diabetic Ketoacidosis (Ketoacidosis, Diabetic) 07/2012
1	Brain Edema (Cerebral Edema) 07/2012
1	Disseminated Intravascular Coagulation 01/2011
1	Inflammation (Inflammations) 01/2011
1	Thrombotic Thrombocytopenic Purpura 01/2011
1	Pulmonary Hypertension 02/2009
1	Adrenal Insufficiency (Adrenal Gland Hypofunction) 02/2009
1	Endotoxemia 02/2009
1	Thrombocytopenia (Thrombopenia) 10/2008
1	Hypersensitivity (Allergy) 10/2003
1	Bacterial Infections (Bacterial Infection) 01/2003
1	Hypoxia (Hypoxemia) 05/2002
1	Craniocerebral Trauma (Head Injury) 01/2002
1	Traumatic Brain Injuries (Traumatic Brain Injury) 01/2002
1	Wounds and Injuries (Trauma) 01/2002

Drug/Important Bio-Agent (IBA)

2	ProcalcitoninIBA 01/2003 - 01/2002
1	CatecholaminesIBA 12/2018
1	Oxygen (Dioxygen)IBA 01/2017
1	Mannitol (Osmitrol)FDA LinkGeneric 07/2012
1	Dacarbazine (DIC)FDA LinkGeneric 01/2011
1	thiamine triphosphorate (TTP)IBA 01/2011
1	Vasodilator Agents (Vasodilators)IBA 02/2009
1	Hydrocortisone (Cortisol)FDA LinkGeneric 02/2009
1	Nitric Oxide (Nitrogen Monoxide)FDA Link 02/2009
1	Metalloproteases (Metalloproteinases)IBA 10/2008
1	AntigensIBA 10/2008
1	Plasminogen Activators (Plasminogen Activator)IBA 10/2008
1	von Willebrand FactorIBA 10/2008
1	ADAMTS13 ProteinIBA 10/2008
1	DisintegrinsIBA 10/2008
1	ThrombospondinsIBA 10/2008
1	Glucose (Dextrose)FDA LinkGeneric 10/2003
1	Glutamic Acid (Glutamate)FDA Link 10/2003
1	NAD (NADH)IBA 05/2002
1	CytokinesIBA 05/2002
1	EnzymesIBA 05/2002
1	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 05/2002

Therapy/Procedure

6	Therapeutics 12/2018 - 10/2003
3	Plasma Exchange 05/2015 - 10/2008
3	Resuscitation 06/2011 - 10/2003
2	Artificial Respiration (Mechanical Ventilation) 12/2018 - 07/2012
2	Extracorporeal Membrane Oxygenation 05/2015 - 02/2009
2	Catheters 07/2012 - 01/2002
2	Critical Care (Surgical Intensive Care) 02/2009 - 10/2003
1	Ventriculostomy 07/2012
1	Continuous Renal Replacement Therapy 04/2012